Successful commercialization of Prevymis® (Letermovir) by Merck & Co., USA (MSD): In 2012 AiCuris entered into an exclusive worldwide license agreement for its portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including Letermovir, that resulted in successful registration of the drug on major markets with growing revenues (over $280 million in 2020) and block-buster potential in the upcoming years.
To optimize the royalty flow and to boost the company´s development pipeline, AiCuris signed a deal with Royalty Pharma for a monetization of partial royalty flow for Prevymis®. This deal supports the company´s more expensive development of late-stage assets, while keeping the major part of the royalty and milestones stream with AiCuris.
To explore a radically new approach to fight severe bacterial infections, AiCuris signed a deal with Lysando in 2019. This deal grants AiCuris access to a new technology – Artilysins®, a new class of fusion proteins with a novel mode of action to potentially replace conventional antibiotics. These drugs could provide a breakthrough in fighting antimicrobial resistance (AMR), while also solving indications of urgent unmet need in antibacterial therapy.